Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The culture of doubt: Do medical students really experience clinical uncertainty when they should?

Medical teacher·2024
Same author

[Tolerating uncertainty: Towards a competence-based approach].

La Revue de medecine interne·2022
Same author

Haematological parameters associated with postpartum haemorrhage after vaginal delivery: Results from a French cohort study.

Journal of gynecology obstetrics and human reproduction·2021
Same author

[Patient expectations in asthma care].

Revue des maladies respiratoires·2021
Same author

Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry.

Thrombosis research·2021
Same author

[Direct oral anticoagulants: In which indications? Which one to prescribe? For or against their use in frail patients and in atypical cases? Which monitoring and management haemorrhage complications?]

La Revue de medecine interne·2020

Related Experiment Video

Updated: Jun 27, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

[Drugs and venous thromboembolism].

K Lacut1, D Mottier, P Pottier

  • 1EA3878, département de médecine interne et pneumologie, CHU de Brest, université de Bretagne-Occidentale, 29609 Brest cedex, France. karine.lacut@chu-brest.fr

Revue De Pneumologie Clinique
|December 17, 2008
PubMed
Summary

Certain medications, including hormone therapies and antipsychotics, increase the risk of venous thromboembolism (VTE). While some drugs like aspirin may reduce VTE risk, further research is needed for practical recommendations.

Related Experiment Videos

Last Updated: Jun 27, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Context:

  • Venous thromboembolism (VTE) is a significant health concern with multifactorial causes.
  • Drug exposure is recognized as a contributing factor to VTE occurrence.
  • Previous research has focused on hormone treatments, but other drug classes are also implicated.

Purpose:

  • To review the association between various drug classes and the risk of venous thromboembolism (VTE).
  • To highlight drugs that may increase VTE risk and those that might offer protection.
  • To underscore the need for further research into the mechanisms and clinical implications of drug-associated VTE.

Summary:

  • Certain drugs, including hormone therapies (oral contraception, HRT), antipsychotics, thalidomide, and dexamethasone, are associated with an increased risk of VTE.
  • The combination of thalidomide and dexamethasone in multiple myeloma treatment significantly elevates VTE risk.
  • The precise physiopathological mechanisms underlying drug-induced prothrombotic effects remain incompletely understood.
  • Conversely, some evidence suggests that aspirin and statins may reduce VTE risk, though definitive recommendations cannot yet be made.

Impact:

  • Informs healthcare providers about potential VTE risks associated with specific medications.
  • Highlights the need for careful patient monitoring when prescribing implicated drugs.
  • Guides future research directions for understanding and managing drug-associated VTE.
  • Emphasizes the potential for certain drugs to mitigate VTE risk, warranting further investigation.